ZMapp, a concoction of three Ebola antibodies, was created in Winnipeg — half a world away from the West African countries where Ebola has left thousands of people dead.

ZMapp, a concoction of three Ebola antibodies, was created in Winnipeg — half a world away from the West African countries where Ebola has left thousands of people dead.

Grand Challenges is a family of initiatives fostering innovation to solve key global health and development problems. Each initiative is an experiment in the use of challenges to focus innovation on m...

A Liberian doctor has died despite taking experimental an...

Experts call for speedy testing of drugs to fight the killer disease, insisting urgent needs of patients should come first

ZMapp, a concoction of three Ebola antibodies, was created in Winnipeg — half a world away from the West African countries where Ebola has left thousands of people dead.

'If I get this wrong, something bad could happen,' one remembers about administering ZMapp

The increased incidence of natural outbreaks caused by EBOV and other filoviruses poses a significant threat to human health globally. The large-scale emergence/re-emergence of EBOV and other highly pathogenic viruses into human populations should be expected to increase in frequency,...

The 2018–2020 Ebola outbreak in the Democratic Republic of Congo (DRC) marked the first major cohort of Ebola survivors treated with advanced therapeutics, including monoclonal antibodies (REGN-EB3, Ansuvimab, ZMapp) and Remdesivir.

MultiSearch Tag Explorer - Explore tags and search results by aéPiot - aéPiot: Independent SEMANTIC Web 4.0 Infrastructure (Est. 2009). High-density Functional Semantic Connectivity with 100/100 Trust...

Informer & Inspirer

Informer & Inspirer

ZMapp was able to reverse Ebola's progression in 18 monkeys—even ones that had already been infected for five days, according to a new study published in Nature.

An experimental Ebola drug called ZMapp was given to two ...

ZMapp, a concoction of three Ebola antibodies, was created in Winnipeg — half a world away from the West African countries where Ebola has left thousands of people dead.

The 2018–2020 Ebola outbreak in the Democratic Republic of the Congo marked the first major cohort of Ebola survivors treated with advanced therapeutics, including monoclonal antibodies (REGN-EB3, ansuvimab, ZMapp) and remdesivir. This study explored factors influencing long-term sequelae in survivors who received these specific therapies.MethodsA prospective multicenter study enrolled 750 Ebola survivors from the 10th outbreak in the Democratic Republic of the Congo between April and October 2020. Participants were followed for 12 months to assess the recurrence of clinical sequelae according to Weibull and shared frailty models.ResultsOf 750 of Ebola survivors, 650 (86.7%) experienced post-Ebola sequalae. The median age of survivors was 32 years and 56.7% were female. Among them, 463 (61.7%) experienced neurologic sequelae, 373 (49.7%) musculoskeletal sequelae, and 288 (38.4%) general sequelae. Globally, these persisted for at least 38 months postdischarge, with slight decreases over time. At enrollment (median time to baseline visit, 330 days after discharge), neurologic sequelae were more frequent in the REGN-EB3 group (hazard ratio, 2.14; 95% CI, 1.28–3.57) as compared with the remdesivir group. Musculoskeletal sequelae were associated with age (1.02; 1.00–1.03), ZMapp treatment (3.17; 1.81–5.56), and acute-phase hemorrhagic symptoms (1.64; 1.14–2.36). Ocular sequelae were associated with age (1.04; 1.02–1.06). Female sex, older age, metabolic comorbidities, and REGN-EB3 therapy were associated with recurrent neurologic and musculoskeletal sequelae. Recurrent ocular sequelae were more frequent in adults (1.02; 1.01–1.03).ConclusionsDespite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group and musculoskeletal sequelae in the ZMapp group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.

The 2018–2020 Ebola outbreak in the Democratic Republic of Congo (DRC) marked the first major cohort of Ebola survivors treated with advanced therapeutics, including monoclonal antibodies (REGN-EB3, Ansuvimab, ZMapp) and Remdesivir. This study explored factors influencing long-term sequelae in survivors who received these specific therapies.MethodsA prospective, multicenter study enrolled 750 Ebola survivors from the tenth outbreak in DRC between April and October 2020. Participants were followed for 12 months to assess the recurrence of clinical sequelae using Weibull and shared frailty models.ResultsOverall, 650 (86.7%) of 750 of Ebola survivors experienced post-Ebola sequalae. The median age of survivors was 32 years, and 56.7% were female. Among them, 463 (61.7%) experienced neurologic sequelae, 373 (49.7%) musculoskeletal sequelae, and 288 (38.4%) general sequelae. Globally, these persisted for at least 38 months post-discharge, with slight decreases over time. At enrollment (median time to baseline visit, 330 days after discharge), neurologic sequelae were more frequent in the REGN-EB3 group (Hazard Ratio [HR], 2.14; 95% confidence interval [CI] 1.28-3.57) compared to Remdesivir group. Musculoskeletal sequelae were associated with age (1.02 [1.00-1.03]) , with ZMapp treatment (3.17 [1.81-5.56]), and acute-phase hemorrhagic symptoms (1.64 [1.14-2.36]). Ocular sequelae were associated with age (1.04 [1.02-1.06]). Female sex, older age, metabolic comorbidities and REGN-EB3 therapy were associated with recurrent neurologic and musculoskeletal sequelae. Recurrent ocular sequelae were more frequent in adults (1.02 [1.01-1.03]).ConclusionsDespite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group, and musculoskeletal in ZMapp group compared to the Remdesivir group, also among older survivors, women and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.